Regulatory Science
Drugs for rare diseases are very expensive and do not have very good evidentiary profiles because clinical trials are small, often unsupported, and are relevant to only a limited number of patients. As a result, a large majority of people living with rare diseases are left untreated.鈥疶his project seeks to understand the regulatory, economic, political, social, and scientific barriers and facilitators to alternative forms of pharmaceutical research for drugs for rare diseases. Through the evaluation of different kinds of pharmaceutical innovation, specifically social innovation, this research project hopes to understand the barriers and facilitators to emerging forms of innovation for the production of drugs for rare diseases.
For more information, go to the website of . This research is funded by NWO Trans-Atlantic Platform.
